# Study to Evaluate the Safety and Tolerability of FX201 in Patients with Osteoarthritis of the Knee

> **NCT04119687** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Pacira Pharmaceuticals, Inc** · enrollment: 72 (actual)

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **BIOLOGICAL:** FX201

## Key facts

- **NCT ID:** NCT04119687
- **Lead sponsor:** Pacira Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-02
- **Primary completion:** 2023-11-28
- **Final completion:** 2026-11-28
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04119687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04119687, "Study to Evaluate the Safety and Tolerability of FX201 in Patients with Osteoarthritis of the Knee". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04119687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*